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Summary.-Theeffects oflong-termanticoagulation withphenprocoumonongrowth
of the Lewis lung carcinoma (3LL) were studied. Oral anticoagulation initiated at
the day of i.m. transplantation of the 3LL into C57BL mice significantly inhibited
primary tumour growth and reduced the number of spontaneous metastases to the
lungs. Intermittent anticoagulation was without effect on metastasis formation but
still retarded primary growth. There was no influence of anticoagulation on the
mean survival time (MST) oftumour-bearing animals. Phenprocoumon appears to
improve the results ofcyclophosphamide or 5-fluorouracil treatment, but there were
no statististically significant differences. In contrast, bleomycin treatment in com-
bination with adjuvant anticoagulation suggested a possible drug synergy. No
significant influence of anticoagulation on the response of the primary tumour to
irradiation wasfound, though the MST ofirradiated and anticoagulated animals was
greater than in the solely irradiated controls. The present investigations suggest
that coumarin derivatives have some direct tumour-inhibiting capacities, but exert
their antimetastatic action via deceleration of the blood clotting mechanism.
FIBRIN formation around intravascular
tumour cell emboli is considered to be of
importance for the establishment of hae-
matogenous metastases (Wood, 1971).
On the other hand, fibrin has been
detected within and around solid tumours,
and it was assumed that this would favour
the invasive growth of malignant tissue
(O'Meara and Jackson, 1958). Under
experimental conditions, the pharma-
cological alteration of the host's clotting
mechanism suggested the pathogenic
significance of blood coagulation in the
growth and dissemination of tumours
(Wood, 1974). Various anticoagulants
have been used to influence the spread of
rodent tumours, yet many of the results
reported are contradictory. The experi-
mental systems most widely used were
lung colony assays after i.v. injection of
tumour cell suspensions. Since these
systems are highly artificial and do not
correlate with any known clinical con-
dition, the interest has focused on
spontaneously metastasising tumours.
Since the first report of the effects of
dicumarol on circulating Brown-Pearce
carcinoma cells in rabbits by Strauss and
Saphir (1949), anticoagulation with
coumarin derivatives has been a frequent
approach to altering the blood coagula-
bility of tumour-bearing animals
(Hagmar, 1970).
The present investigations deal with
the effects of controlled long-term anti-
coagulation on primary and metastatic
growth ofthe spontaneously metastasising
Lewis lung carcinoma (3LL). Further-
more, some effects of anticoagulation in
combination with conventional chemo-
therapy and radiotherapy were investi-
gated.
MATERIAL AND METHODS
Animals.-C57BL/6 J-Han spf mice of
both sexes were used throughout the experi-
ments. The weight range was between 17ANTICOAGULANT EFFECTS ON METASTASIS
and 22 g. The animals were fed with
commercial pellets (Altromin8) and allowed
to drink tap water ad libitum.
Lewris lung carcinama.-This tumour ori-
ginated spontaneously as a carcinoma of the
lung of a C57BL mouse in Dr Lewis' lab-
oratory at the Wistar Institute in 1951. Our
tumour was obtained from Prof. K. Karrer
(Institute of Cancer Research, University of
Vienna) and it was maintained by s.c.
implants of5 x 101 tumour cells into C57BL
mice, with passage every 14 days. Tumour
cell suspensions were obtained by homo-
genization of solid fragments in sterile saline
(containing 250 u/ml streptomycin and 500
u/ml penicillin). The tumour cell count was
adjusted to the appropriate concentration
with sterile, pyrogen-free saline. Experi-
mental animals were transplanted i.m. with
5 X 106 tumour cells into the left hind leg.
Anticoagulation.-Phenprocoumon (Mar-
cumar t, Hoffmann-La Roche, Basle) was
added to the drinking water at concen-
trations ranging from 2 mg to 8 mg/l tap
water. The degree of anticoagulation was
measured by the Thrombotest method:
0{003 ml of tail-vein blood was added to
0-3 ml of Thrombotest reagent (Nyegaard,
Oslo) and the clotting time was recorded
automatically. Using this method, the
normal range in mice (n = 35) was estab-
lished to be 46-54 s. The phenprocoumon
dose was checked dailv in order to prolong
the Thrombotest clotting time of the
experimental animals to 150-200s through-
out the entire experiments. Three different
animals from each test group were used in
alternating sequence to monitor the clotting
times. Unless otherwise stated, anticoagu-
lation was initiated at the davs of tumour
transplantation and continued until the end
of each experiment.
In some experiments. short-term anti-
coagulation was initiated by i.p. injection of
phenprocoumon in a concentration of 2-5
mg/kg body weight every 24 h.
Chemotherapy.-(a) Cyclophosphamide
(Asta-Werke, Brackwede) was administered
i.p. on two consecutive davs. in a dose of
30 mg/kg body weight per day, starting Day
7 after tumour transplantation. (b) 5-
Fluorouracil (Hoffinann-La Roche, Basle)
was given i.p. in a single dose of 15 mg/kg
body weight on Day 12 after tumour trans-
plantation. (c) Bleomycin (Mack, Illertissen)
was injected on 3 consecutive days i.p.at a
6
dose of 15 mg/kg body weight per day,
starting Day 12 after tumour transplantation.
Irradiation.-Single doses of 2000 rad
were given, using opposing field technique.
Ten days after tumour transplantation, the
tumour-bearing leg was locally irradiated
with a 6OCo source fitted with a tube colli-
mator of 3 cm diameter. The dose rate
was 199 rad/min at an SSD of 46-6 cm. The
field inhomogeneity in the target volume was
less than ± 2%.
Evaluation of tumour grotth and lung
metastses.-Tumour growth curves were
calculated by the approximate tumour
weights from measurement of tumour dia-
meters with a Vernier caliper. The longest
and shortest diameters were measured in mm,
and the mass expressed in mg by multiplying
the length of the tumour by the width
squared and dividing the product by 2
(tumour weight (mg) = 1 x w2/2). After
sacrifice ofthe animals, thelungs werestained
in situ through the trachea with 12% Indian
ink, and the macroscopically visible lung
metastases were counted (Wexler, 1965).
Survival studies.-Survival studies were
carried out (a) in control and anticoagulated
tumour-bearing animals and (b) in irradiated
tumour-bearing animals with and without
adjuvant anticoagulation. The mean sur-
vival time (MST) was calculated after ces-
sation oftheanticoagulant therapy on Day 15
after tumour transplantation. The ratio of
the 3MST of the treated group to the MST of
the corresponding control group (T/C) was
expressed as %.
Stati8tical evaluation.-The statistical
analysis of tumour weight and lung metas-
tases data in each experimental group was
carried out using the U test for two random
variables according to Wilcoxon, Mann and
Whitney.
RESULTS
Anticoagukltion
Theoralmedicationofphenprocoumon,
with daily adjustmentofthedose, resulted
in a stable state of anticoagulation
throughout the entire study. Death from
haemorrhage was infrequent, the loss of
animals within a single experiment in the
anticoagulated groups never exceeding
10%. During the experiments, all ani-
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mals were regularly weighed, and the
weight gain in control and anticoagulated
groups was always identical. An ex-
ample of the weight development in
control (n- 30) and phenprocoumon-
treated (n 40) tumour-bearing animals
is given in Table I.
TABLE I.-Body Weight ofTumour-bearing
Animals
Tumour animal body weight (g)
, s 5~~~
Days after
transplantation
Day 0
Day 12
Day 20
Control
Xr 8.e.
18-8 0 5
21-2 0 3
22-8 0-6
Phenprocoumon
x s.e.
19-5 0-3
18-6 1 0
22-2 0 3
significant effect was seen if the drug was
administered from Days 1-10 of tumour
growth (P < 0.05). However, there was
still some tumour inhibition by short-
term treatment (Days 4-9 and Days 7-9,
Fig. 2).
4.-
gram
3-
2-
1-
Phenprocoumon was added to the drinking water
from Days 0-20.
Effect ofanticoagulation onprimary tumour
growth
This is shown in Fig. 1 by the growth
curves oftumours in control (n = 12) and
anticoagulated animals (n = 15). Phen-
procoumon was given throughout the
entire period of tumour growth. It is
obvious that there was a significant
inhibition of tumour growth on Day 12
(P< 0-01). In another experiment, the
influence of limited anticoagulation on
tumour growth was tested in 3 groups of
10 animals each. Anticoagulation was
established by i.p. injections of phen-
procoumon. The maximum and most
gram
0J
I
/,i
I
Control 1-10 4-9 7-9
days of anticoagulation
FIG. 2.-Effect of various anticoagulation
regimens on tumour weight (g) on Day 12
after transplantation (oral anticoagulation
Days 1-10, i.p. anticoagulation Days 4-9
and Days 7-9).
Metastastic growth of lung tumours
The metastatic growth oflung tumours
in control and anticoagulated animals is
shown in Fig. 3. Each group consisted
of 30 animals. Oral anticoagulation was
maintained from the day of tumour
transplantation until the end of the
mean no. of
lung metastases
% animals with
lung metastases
3 0
2-5
2-0
1-5
1 0
8-
7.
6
5.
4.
3.
2
1I
0-
6 8 10 12 days
FIG. 1.-Growth curves of the early Lewis
lung carcinoma in anticoagulated (orally,
Days O0i2) and control mice.
100
50-
0
Control Phenpro-
coumon
FIG. 3.-Mean number of metastases in both
lungs and % animals with lung metastases
in anticoagulated (orally, Days 0-20) and
control mice.
I
Control Phenpro -
coumon 70
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experiment (Day 20). The reduction
of the mean number oflung metastases in
the phenprocoumon-treated group was
statistically highly significant (P 0 002).
Whereas all animals in the control group
had lung metastases, only 50% of the
anticoagulated animals had macroscopical
evidence of lung tumour. As shown in
Table II, short-term anticoagulation was
ineffective in reducing lung metastases.
Only those animals receiving phenpro-
coumon from Days 0-20 had significantly
fewer lung tumours, thus confirming the
previous experiment (Fig. 3). Short-
term therapy (Days 7-9) was given i.p.,
whereas treatment from Days 0-11,
0-20 and intermittent anticoagulation
(Days 0-20) was oral.
Survival studies
The MST of 12 control animals bearing
the Lewis lung carcinoma was 29-4 days.
Anticoagulation from Day 0 to 15 resulted
in a MST of 31*1 days in 15 animals, T/C
thus being 106%. This difference is not
statistically significant. Fig. 4 demon-
strates the distribution of the death rates
in the two groups. It will be noted that,
despite the similar MST, the onset of
death of the anticoagulated animals was
clearly delayed.
Anticoagulation and chemotherapy
In all experiments, phenprocoumon
was given from Day 0 until the end ofthe
study (Day 16 or 19). The effect of
% animals
10UI
50
25 30
------ anticoagulated
.s days
FIG. 4.-Distribution of death rates in
tumour-bearing mice with and without
anticoagulation (orally, Days 0-15).
cyclophosphamide treatment alone, and in
combination with anticoagulation, on
primary and metastatic tumour growth is
shown in Fig. 5. There was a slight
flattening of the growth curve after
cyclophosphamide treatment; the com-
bination of cyclophosphamide with anti-
coagulation improved the results some-
what. The reduction in lung metastasis
by adjuvant anticoagulation was statis-
tically not significant. Similar effects
were found when anticoagulation was
combined with 5-fluorouracil treatment
(Fig. 6). In contrast, the combination of
bleomycin and anticoagulation resulted in
a highly significant tumour inhibition
when compared to bleomycin alone (P =
0'-1). The effect on the metastatic
gram
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FIG. 5.-Tumour growtth curves, mean number of metastases in both lungs, and % animals with and
without lung metastases, in control, cyclophosphamide (Cyclo) and Cyclo + phenprocoumon
(Cyclo + A) (orally, Days 0-16) treated animals.
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FIG. 6.-Tumour growth curves, mean number ofmetastases in both lungs, and % animals with and
without lung metastases, in control, 5-fluorouracil (5-FU) and 5-FU + phenprocoumon (5-FIX + A)
(orally, Days 0-19) treated animals.
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FeIG. 7.-Tumour growth curves, mean number ofmetastases in both lungs, and % animals with and
without lung metastases, in control, bleomycin (Bleo) and Bleo + phenprocoumon (Bleo + A) (orally, Days 0-19) treated animals.
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Fia. 8.-Tumour growth curves of control, tumour-irradiated and tumour-irradiated animals with
adjuvant anticoagulation (orally, Days 0-15).
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growth, however, was not significant
(Fig. 7).
Anticoagulation and irradiation
Fig. 8 shows the tumour growth curves
of control (n_ 12), tumour-irradiated
(n 12) and tumour-irradiated animals
with concomitant anticoagulation (n
15). Tumour irradiation on Day 11 led
to a significant retardation of tumour
growth, but statistical analysis ofthe data
did not reveal any additive effect of
% animals
100
50
-anticoagulated+ 2000rad
Fic. 9.-Distribution of death rates in
tumour-bearing mice after tumour irradia-
tion on Day 11, with and without anti-
coagulation (orally, Days 0-15).
concomitant anticoagulation. The MST
of the irradiated mice was 30 3 days,
anticoagulation increased the MST of the
irradiated animals to 33*1 days, the T/C
being 11000. Yet the distribution of
death rates shows that there is a high
proportion of animals in the anticoagu-
lated group (35%0) which outlives the
corresponding control group.
DISCUSSION
Since long-term anticoagulation in
animals bearing spontaneously metasta-
sising tumours resulted in considerable
variations of the metastastic behaviour
(Hagmar, 1970), other pharmacological
actions of the anticoagulants used have
been discussed (Hilgard et al., 1972;
Thornes, Edlow and Wood, 1968). The
present investigations show two distinct
effects of long-term anticoagulation with
phenprocoumon on the growth pattern of
the syngeneic, spontaneously metastasis-
ing Lewis lung carcinoma of mice: (a)
inhibition of primary tumour growth and
(b) reduction of metastases to the lung.
Previous investigations into the effect
of coumarin anticoagulation on metastasis
formation have applied standard doses of
the oral anticoagulant throughout the
experiments (Brown, 1973; Ryan,
Ketcham and Wexler, 1968). No data
concerning the toxicity were given in
these studies. In our experience, death
from haemorrhage is a frequent event
which is closely related to the degree of
anticoagulation. Since, in the present
investigations, anticoagulant therapy was
daily monitored and individually adjusted
in each experiment, toxic deaths were
almost eliminated. The body weight
development of anticoagulated and cor-
responding control animals was identical
in each experiment, indicating that drug
toxicity was minimal (Table I). This is
important in the light of the known
sensitivity of the Lewis lung carcinoma to
variations of the host's weight gain.
Continuous oral anticoagulation led to
a depression of the growth curves of the
primary tumour, and it seemed that this
effect was not directly related to the
metastasis-inhibiting capacity of this
therapy. Evenshort-term i.p. application
of phenprocoumon led to some inhibition
of primary tumour growth (Fig. 2),
whereas only continuous oral long-term
anticoagulation was effective in preventing
tumour metastasis (Table II). Inter-
mittent phenprocoumon therapy through-
out the period of tumour growth had no
antimetastatic effect, indicating that the
reduction of pulmonary metastasis could
be mediated by the deceleration of the
clotting mechanism (Brown, 1973), thus
requiring a stable state of anticoagulation.
An effect of anticoagulation on the early
release of viable tumour cells, as a con-
sequence ofeffects on the primary tumour,
is unlikely, since phenprocoumon therapy
throughout the first 10 days after tumour
transplantation did not prevent lung
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TABLE II.-The Effect of Various Anti-
coagulation Regimes on Spontaneous
Lung Metastasis Formation.
Mean no. of lung metastases
nlrntirnf of n-
anticoagulant
therapy
Day 7- 9
Day 0-11
Intermittent
Day 0-20
Day 0-20
Treated Control P
x s.e. x s.e.
24-6 3-5 21-5 1 9 >0-1
29-2 5 9 27-0 5-1 >0-1
38-7 14-0 35.0 5 9 >0-1
12-1 4-2 27-0 5-1 <0 05
Short-term anticoagulation (Days 7-9) was
established by i.p. injections of phenprocoumon.
Long-term anticoagulation (Days 0-1 1, intermittent
Days 0-20 and continuous Days 0-20) was obtained
by oral administration of phenprocoumon.
metastases (Table II). The mechanism of
retardation of primary tumour growth by
phenprocoumon therapy remains obscure.
There is no evidence for a direct cyto-
toxicityofphenprocoumon intherapeutical
doses: preincubation of 3LL cells with
phenprocoumon prior to implantation did
not alter the kinetics of tumour growth,
andanticoagulation throughout thegrowth
of the lymphoid leukaemia L1210 in
DBA/2 mice did not influence the MST
of these animals (Hilgard, unpub.).
Reduced fibrin formation within the
primary tumour does not seem to be a
significant explanation for the growth-
retarding effect of anticoagulation, since
continuous defibrination of the animals
with ancrod had no significant influence
on the growth of i.m. transplanted 3LL
(Hilgard, unpub.).
The mean survival time of tumour-
bearing animals was not significantly
prolonged by long-term anticoagulation,
but it must be taken into consideration
that in the present survival studies
phenprocoumon therapy was discontinued
on Day 15 after tumour transplantation
since it was our aim to clearly separate any
possible death from haemorrhage from
tumour-related deaths. The later onset
of deaths in the treated group, however,
could be an expression of the positive
effects of anticoagulation on the quality
of life of the tumour-bearing animals.
Under clinical conditions, a beneficial
effect of oral anticoagulants in combina-
tion with chemotherapy was recently
reported (Thornes, 1975). However, al-
most no experimental evidence is currently
available to support the rationale of
combining anticoagulation with conven-
tional chemotherapy. In the present
study, two days of cyclophosphamide and
a single dose of 5-fluorouracil resulted in a
slight inhibition of primary tumour
growth, but were highly effective in reduc-
ing pulmonary metastases (Fig. 5 and 6).
The combination of these drugs with
continuous anticoagulation improved the
therapeutical effects. The triple injection
of bleomycin resulted only in a slight
inhibition of primary tumour growth, yet
it was effective in reducing pulmonary
metastases (Fig. 7). The combined treat-
ment of long-term anticoagulation and
bleomycin suggested drug synergy, al-
though the antimetastatic effects of this
combined treatment were not pronounced.
The combination of anticoagulation
with local tumour irradiation had no
obvious synergistic effects on primary
tumour growth when compared to irradi-
ation alone. The analysis of the death
rates of animals with this combined treat-
ment schedule, however, indicates that the
prevention of lung metastases by oral
anticoagulation was effective in approxi-
mately one third of the tumour-bearing
mice, leading to a prolongation of the
life span of these animals.
From the present experiments, it can
be concluded that anticoagulation with
coumarin derivatives is effective in re-
ducing the growth and spread of a
malignant tumour. It seems rational to
take advantage of this capacity and to
combine oral anticoagulation with con-
ventional chemotherapy or radiotherapy.
The present animal data suggest that
additive actions against the tumour could
reduce the toxicity of cytotoxic drugs,
and preliminary clinical data indicate that
anticoagulants are comparatively safe,
even in advanced cancer (Elias, Shukla
and Mink, 1975). Our data provide an
experimental background for the clinicalATNTICOAGULANT EFFECTS ON METASTASIS 85
use ofthese drugs in the adjuvant therapy
of disseminating malignant tumours.
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